Summit, New Jersey-based Kenvue Inc. (KVUE) is a global consumer health company offering everyday health and wellness products through iconic brands. Its portfolio helps consumers care for themselves and their families, with products spanning personal care, skincare, oral care, and over-the-counter health categories worldwide. It has a market capitalization of approximately $34.1 billion.
Companies valued between $10 billion and $200 billion are generally classified as “large-cap stocks,” and Kenvue comfortably fits this category. Its substantial market capitalization reflects its size, influence, and established position within the household and personal products industry. Kenvue stands out for its trusted consumer health brands and promising momentum in Skin Health and Beauty. Its strong gross margins, international presence, and progress in China provide additional support, while favorable foreign exchange movements could help offset some of the company’s near-term challenges.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Despite these strengths, KVUE has slipped 11.7% from its 52-week high of $20.13, reached on July 7, 2026. Over the past three months, KVUE shares have dipped 1.6%, underperforming the Nasdaq Composite ($NASX), which has gained 2% over the same period.
www.barchart.com Shares of KVUE have gained 3.1% year-to-date and declined 5.7% over the past 52 weeks, significantly underperforming the Nasdaq Composite’s 13.3% year-to-date gain and 19.5% return over the same period.
KVUE has remained below its 50-day moving average since late August and recently fell below its 200-day moving average in early September, indicating downward momentum.
www.barchart.com Kenvue has lagged the broader market amid margin pressure from inflation, tariffs and currency-related costs. More recently, its underperformance has also coincided with renewed legal uncertainty surrounding Tylenol. On July 13, a federal appeals court revived more than 500 private lawsuits alleging a link between Tylenol use during pregnancy and autism and ADHD, sending Kenvue shares down 1.8% in afternoon trading.
The Procter & Gamble Company (PG), one of KVUE’s key competitors, has underperformed KVUE both year-to-date and over the past year, with shares rising 1.4% YTD and falling 8.4% over the past year.
Wall Street analysts remain neutral on KVUE’s prospects. The stock carries a consensus “Hold” rating from the 13 analysts covering it. The mean price target of $19.33 implies 8.7% upside from its current price.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Dear UnitedHealth Stock Fans, Mark Your Calendars for October 1 Foxconn Just Delivered a Major Bullish Signal for Nvidia Stock Why AMD Stock Forecast Has Room to Run ‘Not a Marketing Stunt’ — Ex-OpenAI and Anthropic Researcher Who Quit Explains Why They Keep Building AI That ‘Could Kill Us All’ Within 10 Years